Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study

References

• Dela Cruz C, Tanoue L, Matthay R. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605–644. doi:10.1016/j.ccm.2011.09.00122054876
   PubMed Web of Science ®Google Scholar
• Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small cell-lung cancer: implications for current and future therapies. J Chin Oncol. 2013;31:1039–1049.
   PubMed Web of Science ®Google Scholar
• Itsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol. 2010;40:101–106. doi:10.1093/jjco/hyp17420031962
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186. doi:10.1056/NEJM1971111828521084938153
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027. doi:10.1200/JCO.2005.06.08115585754
   PubMed Web of Science ®Google Scholar
• Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist. 2005;10(6):382–391. doi:10.1634/theoncologist.10-6-38215967832
   PubMed Web of Science ®Google Scholar
• Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharmacol Ther. 2016;164:204–225. doi:10.1016/j.pharmthera.2016.06.00127288725
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.17167137
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised Phase 3 trial. Lancet. 2014;384:665–673. doi:10.1016/S0140-6736(14)60845-X24933332
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191. doi:10.1200/JCO.2004.11.02215169807
   PubMed Web of Science ®Google Scholar
• Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol. 2009;27:1405–1412. doi:10.1200/JCO.2008.16.241219224857
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219–3225. doi:10.1200/JCO.2013.48.858523918952
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454. doi:10.1200/JCO.2015.63.599526884585
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Xu B, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961–1969. doi:10.1002/ijc.2882924604288
   PubMed Web of Science ®Google Scholar
• Song ZB, Yu XM, Lou GY, Shi X, Zhang YP. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther. 2017;10:1821–1825. doi:10.2147/OTT.S11343528367065
   PubMed Web of Science ®Google Scholar
• Zeng DX, Wang CG, Lei W, Huang JA, Jiang JH. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget. 2017;8(39):66248–66253. doi:10.18632/oncotarget.1990829029508
   PubMedGoogle Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103. doi:10.1200/JCO.2000.18.10.209510811675
   PubMed Web of Science ®Google Scholar
• Ding L, Li QJ, You KY, Jiang ZM, Yao HR. The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature. Medicine. 2016;95(20):e3598. doi:10.1097/MD.000000000000359827196461
   PubMed Web of Science ®Google Scholar
• Lin C, Wang S, Xie W, Zheng R, Gan Y, Chang J. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget. 2016;7:59236–59244. doi:10.18632/oncotarget.1098527494860
   PubMedGoogle Scholar
• Zeng DX, Lei W, Wang CG, Huang JA, Jiang JH. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol. 2019;83:439–442. doi:10.1007/s00280-018-3743-030547193
   PubMed Web of Science ®Google Scholar
• Liu X, Qin S, Wang Z, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10(1):153. doi:10.1186/s13045-017-0521-028870253
   PubMedGoogle Scholar